Security
ACADIA Pharmaceuticals Inc. Common Stock · ACAD
ACADNASDAQCommon stockCurrentCIK 1070494Updated Nov 2, 2026
ACAD price & chart
Loading TradingView…
NASDAQ:ACAD on TradingView ↗About the company
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD ↗
Seeking Alpha
Acadia, Zydus patent litigation case looks resolved, says RBC ↗
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results ↗
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript ↗
SEC disclosures
ACADIA PHARMACEUTICALS INC files 8-K: Material Event ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Other Events
Items 8.01, 9.01
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,330,771,000Source | 976,868,000Source | 1,742,900,000Source | 1,225,555,000Source | 914,099,000Source | 1,605,230,000Source | 1,132,364,000Source | 855,103,000Source | 1,564,195,000Source | 1,187,756,000Source | 748,956,000Source | 587,812,000Source |
| Property, Plant and Equipment, NetUSD | 3,708,000Source | 3,988,000Source | 17,107,000Source | 3,547,000Source | 4,144,000Source | 14,652,000Source | 3,498,000Source | 4,370,000Source | 7,511,000Source | 4,215,000Source | 4,612,000Source | 6,021,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 257,996,000Source | 155,149,000Source | 384,985,000Source | 253,637,000Source | 177,134,000Source | 282,212,000Source | 217,696,000Source | 204,745,000Source | 177,695,000Source | 319,589,000Source | 188,657,000Source | 114,846,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 115,850,000Source | 98,209,000Source | 150,642,000Source | 107,505,000Source | 103,698,000Source | 135,350,000Source | 105,743,000Source | 94,701,000Source | 121,457,000Source | 98,739,000Source | 98,267,000Source | 62,195,000Source |
| Inventory, NetUSD | 105,985,000Source | 86,740,000Source | 108,673,000Source | 110,526,000Source | 86,069,000Source | 112,293,000Source | 102,973,000Source | 66,643,000Source | 111,374,000Source | 91,690,000Source | 40,447,000Source | 11,560,000Source |
| Assets, CurrentUSD | 1,076,422,000Source | 788,284,000Source | 1,224,545,000Source | 960,553,000Source | 728,916,000Source | 1,096,016,000Source | 870,942,000Source | 675,296,000Source | 1,062,113,000Source | 938,318,000Source | 616,125,000Source | 507,937,000Source |
| Operating Lease, Right-of-Use AssetUSD | 49,673,000Source | 44,253,000Source | 69,424,000Source | 50,991,000Source | 52,390,000Source | 46,274,000Source | 50,614,000Source | 54,280,000Source | 47,354,000Source | 46,571,000Source | 51,855,000Source | 55,573,000Source |
| Other Assets, NoncurrentUSD | 2,994,000Source | 359,000Source | 3,550,000Source | 2,253,000Source | 476,000Source | 3,928,000Source | 1,455,000Source | 476,000Source | 3,896,000Source | 359,000Source | 476,000Source | 7,587,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 413,499,000Source | 399,688,000Source | 436,291,000Source | 403,173,000Source | 397,399,000Source | 357,164,000Source | 367,127,000Source | 391,059,000Source | 336,805,000Source | 454,963,000Source | 317,201,000Source | 187,399,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source | 16,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,086,954,000Source | -2,348,128,000Source | -1,778,249,000Source | -2,158,733,000Source | -2,380,893,000Source | -1,809,749,000Source | -2,185,399,000Source | -2,414,282,000Source | -1,813,386,000Source | -2,204,386,000Source | -2,430,837,000Source | -2,369,551,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 989,000Source | 858,000Source | -958,000Source | 406,000Source | -339,000Source | -563,000Source | 437,000Source | -229,000Source | 1,445,000Source | 292,000Source | 24,000Source | -975,000Source |
| Stockholders' Equity Attributable to ParentUSD | 917,272,000Source | 577,180,000Source | 1,306,609,000Source | 822,382,000Source | 516,700,000Source | 1,248,066,000Source | 765,237,000Source | 464,044,000Source | 1,227,390,000Source | 732,793,000Source | 431,755,000Source | 400,413,000Source |
| Additional Paid in Capital, Common StockUSD | 3,003,221,000Source | 2,924,434,000Source | 3,085,800,000Source | 2,980,693,000Source | 2,897,916,000Source | 3,058,362,000Source | 2,950,183,000Source | 2,878,539,000Source | 3,039,315,000Source | 2,936,871,000Source | 2,862,552,000Source | 2,770,923,000Source |
| Liabilities and EquityUSD | 1,330,771,000Source | 976,868,000Source | 1,742,900,000Source | 1,225,555,000Source | 914,099,000Source | 1,605,230,000Source | 1,132,364,000Source | 855,103,000Source | 1,564,195,000Source | 1,187,756,000Source | 748,956,000Source | 587,812,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 356,584,000Source | 343,945,000Source | 361,436,000Source | 330,024,000Source | 337,851,000Source | 305,524,000Source | 302,530,000Source | 330,597,000Source | 277,114,000Source | 394,870,000Source | 254,254,000Source | 125,630,000Source |
| Operating Lease, Liability, CurrentUSD | 11,783,000Source | 8,949,000Source | 14,307,000Source | 11,693,000Source | 10,470,000Source | 11,791,000Source | 11,372,000Source | 10,453,000Source | 11,633,000Source | 9,958,000Source | 9,405,000Source | 9,305,000Source |
| Accounts Payable, CurrentUSD | 21,747,000Source | 19,081,000Source | 44,566,000Source | 20,097,000Source | 19,882,000Source | 12,246,000Source | 18,095,000Source | 19,332,000Source | 10,903,000Source | 16,192,000Source | 17,543,000Source | 12,746,000Source |
| Operating Lease, Liability, NoncurrentUSD | 43,026,000Source | 40,421,000Source | 59,547,000Source | 44,601,000Source | 47,186,000Source | 39,003,000Source | 44,634,000Source | 49,189,000Source | 40,554,000Source | 42,037,000Source | 47,800,000Source | 52,695,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 11,162,000Source | 11,423,000Source | 12,393,000Source | 13,232,000Source |
| Other Liabilities, NoncurrentUSD | 13,889,000Source | 15,322,000Source | 15,308,000Source | 28,548,000Source | 12,362,000Source | 12,637,000Source | 19,963,000Source | 11,273,000Source | 19,137,000Source | 18,056,000Source | 15,147,000Source | 9,074,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 334,837,000Source | 324,864,000Source | 316,870,000Source | 309,927,000Source | 317,969,000Source | 293,278,000Source | 284,435,000Source | 311,265,000Source | 266,211,000Source | 378,678,000Source | 236,711,000Source | 112,884,000Source |
| Prepaid Expense and Other Assets, Current | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 3,637,000Source | 18,987,000Source | 391,000,000Source | 226,451,000Source | -61,286,000Source | -215,975,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 14,698,000Source | 11,380,000Source | 52,135,000Source | 67,049,000Source | 66,421,000Source | 68,201,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 13,893,000Source | 7,004,000Source | 22,718,000Source | 472,000Source | 36,072,000Source | -2,171,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -78,000Source | 10,453,000Source | 18,197,000Source | 49,550,000Source | 28,808,000Source | -2,415,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,343,000Source | 1,903,000Source | -5,289,000Source | -1,351,000Source | 4,797,000Source | 5,870,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -250,324,000Source | 31,624,000Source | 10,250,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 33,981,000Source | 20,323,000Source | 109,836,000Source | 157,719,000Source | 16,702,000Source | -114,035,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 66,281,000Source | -124,049,000Source | -302,564,000Source | -30,538,000Source | 31,998,000Source | 73,241,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 5,212,000Source | 0Source | 4,690,000Source | 523,000Source | 50,000Source | 0Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 4,231,000Source | 1,838,000Source | 49,883,000Source | 6,845,000Source | 25,129,000Source | 8,199,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 104,518,000Source | -101,893,000Source | -142,819,000Source | 133,932,000Source | 73,811,000Source | -32,589,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 25,170,000Source | 19,521,000Source | 5,850,000Source | 2,190,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 13,180,000Source | 26,164,000Source | 16,940,000Source | 14,340,000Source | 14,698,000Source | 11,380,000Source | 52,135,000Source | 67,049,000Source | 66,421,000Source | 68,201,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 2,722,000Source | 2,722,000Source | 10,889,000Source | 14,963,000Source | 4,093,000Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | 271,000Source | 229,000Source | 871,000Source | 920,000Source | 1,459,000Source | 2,026,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 146,515,000Source | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 5,109,000Source | 3,542,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | — | — | — | — | — | — | — | 0Source | 146,515,000Source | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | 138,904,000Source | 258,075,000Source | -51,036,000Source | -213,444,000Source |
| Income Tax Expense (Benefit)USD | — | — | -27,184,000Source | 6,041,000Source | 14,973,000Source | 13,545,000Source | 344,000Source | 8,792,000Source | -252,096,000Source | 31,624,000Source | 10,250,000Source | 2,531,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | — | — | 2,300,000Source | 500,000Source | 900,000Source | 600,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 71,779,000Source | 32,765,000Source | 31,500,000Source | 26,666,000Source | 3,637,000Source | 18,987,000Source | 391,000,000Source | 226,451,000Source | -61,286,000Source | -215,975,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 71,779,000Source | 32,765,000Source | 31,500,000Source | 26,666,000Source | 3,637,000Source | 18,987,000Source | 391,000,000Source | 226,451,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 593,000Source | 576,000Source | 647,000Source | 594,000Source | 542,000Source | 588,000Source | 2,371,000Source | 1,823,000Source | 5,109,000Source | 3,542,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 4,231,000Source | 1,838,000Source | 49,883,000Source | 6,845,000Source | 25,129,000Source | 8,199,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 20,300,000Source | 3,700,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | 0Source | — | — | — | — | — | — | 3,600,000Source | 300,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 278,633,000Source | 250,401,000Source | 307,959,000Source | 264,566,000Source | 268,062,000Source | 244,317,000Source | 1,071,505,000Source | 957,797,000Source | 726,437,000Source | 517,235,000Source |
| Cost of RevenueUSD | — | — | 21,647,000Source | 18,857,000Source | 28,316,000Source | 20,734,000Source | 24,791,000Source | 20,392,000Source | 88,998,000Source | 81,841,000Source | 41,638,000Source | 10,166,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | 133,401,000Source | 133,294,000Source | 160,252,000Source | 133,507,000Source | 171,019,000Source | 126,370,000Source | 548,894,000Source | 488,428,000Source | 406,559,000Source | 369,090,000Source |
| Operating Income (Loss)USD | — | — | 35,756,000Source | 31,644,000Source | 37,836,000Source | 32,374,000Source | -4,616,000Source | 19,290,000Source | 104,811,000Source | 230,794,000Source | -73,379,000Source | -223,596,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 593,000Source | 576,000Source | 647,000Source | 594,000Source | 542,000Source | 588,000Source | 2,371,000Source | 1,823,000Source | 5,109,000Source | 3,542,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 44,595,000Source | 38,806,000Source | 46,473,000Source | 40,211,000Source | 3,981,000Source | 27,779,000Source | 138,904,000Source | 258,075,000Source | -51,036,000Source | -213,444,000Source |
| Income Tax Expense (Benefit)USD | — | — | -27,184,000Source | 6,041,000Source | 14,973,000Source | 13,545,000Source | 344,000Source | 8,792,000Source | -252,096,000Source | 31,624,000Source | 10,250,000Source | 2,531,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 71,779,000Source | 32,765,000Source | 31,500,000Source | 26,666,000Source | 3,637,000Source | 18,987,000Source | 391,000,000Source | 226,451,000Source | -61,286,000Source | -215,975,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.43Source | 0.2Source | 0.18Source | 0.16Source | 0.02Source | 0.11Source | 2.32Source | 1.37Source | -0.37Source | -1.34Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.42Source | 0.2Source | 0.18Source | 0.16Source | 0.02Source | 0.11Source | 2.3Source | 1.36Source | -0.37Source | -1.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 168,836,000Source | 165,974,000Source | 171,603,000Source | 167,827,000Source | 170,517,000Source | 166,808,000Source | 168,356,000Source | 165,717,000Source | 163,819Source | 161,683Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 170,650,000Source | 166,178,000Source | 172,851,000Source | 168,681,000Source | 172,706,000Source | 167,668,000Source | 169,919,000Source | 166,362,000Source | 163,819Source | 161,683Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 2,722,000Source | 2,722,000Source | 10,889,000Source | 14,963,000Source | 4,093,000Source | 0Source |
| Costs and ExpensesUSD | — | — | 242,877,000Source | 218,757,000Source | 270,123,000Source | 232,192,000Source | 272,678,000Source | 225,027,000Source | 966,694,000Source | 727,003,000Source | 799,816,000Source | 740,831,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -1,772,000Source | — | — | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 5,109,000Source | 3,542,000Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 684,799,000Source | 507,068,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 72,159,000Source | 95,845,000Source | -100,215,000Source | -233,216,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | 138,904,000Source | 258,075,000Source | -51,036,000Source | -213,444,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 8,246,000Source | 6,586,000Source | 7,990,000Source | 7,243,000Source | 8,055,000Source | 7,901,000Source | 31,722,000Source | 25,458,000Source | 17,234,000Source | 6,610,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | 71,779,000Source | 32,765,000Source | 31,500,000Source | 26,666,000Source | 3,637,000Source | 18,987,000Source | 391,000,000Source | 226,451,000Source | — | — |
| Research and Development ExpenseUSD | — | — | 87,829,000Source | 66,606,000Source | 81,555,000Source | 77,951,000Source | 76,868,000Source | 78,265,000Source | 328,802,000Source | 303,249,000Source | 351,619,000Source | 361,575,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | 0Source | — | — | — | — | — | — | 3,600,000Source | 300,000Source |
Filing attachments
acad-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results - Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues - Third quarter DAYBUE® GAAP net sales of $140 million, up 39% year-over-year driven by strong uptake of DAYBUE STIX - Third quarter NUPLAZID® GAAP net sales of $202 million, up 12% year-over-year on a non-GAAP adjusted basis - Raises 2026 DAYBUE net sales guidance to $505 - $520 million; n…
Read attachment ↗d168737dex991.htm · 8-K · 2026-09-24
Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect - Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=…
Read attachment ↗d143428dex991.htm · 8-K · 2026-09-11
EX-99.1 2 d143428dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF DERIVATIVE MATTERS TO: ALL PERSONS OR ENTITIES WHO HOLD OR BENEFICIALLY OWN, DIRECTLY OR INDIRECTLY, ACADIA PHARMACEUTICALS, INC. (“ACADIA” OR THE “COMPANY”) COMMON STOCK AS OF JULY 9, 2026 (“CURRENT ACADIA STOCKHOLDERS”) PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL OF THE ABOVE-CAPTIONED STOCKHOLDER DERIVATIVE ACTION …
Read attachment ↗d143428dex992.htm · 8-K · 2026-09-11
EX-99.2 3 d143428dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 WOLF HALDENSTEIN ADLER FREEMAN & HERZ LLP BETSY C. MANIFOLD (182450) 750 B Street, Suite 1820 San Diego, CA 92101 Telephone: (619) 239-4599 Facsimile: (619) 234-4599 Email: manifold@whafh.com Attorneys for Plaintiff [Additional Counsel on Signature Page] UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA LINDA KANNER, TRUSTEE OF THE Case No.: 3:23-cv-02293-WQH-MSB ELLA KANNER REVOCABLE TRUST, …
Read attachment ↗acad-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 acad-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results - Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX - Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis - Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and …
Read attachment ↗acad-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 acad-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance - First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; Successful Launch of DAYBUE STIX Underway - First quarter NUPLAZID®GAAP net sales of $167 million, up 6% year-over-year on a non-GAAP adjusted basis - Reaffirms expectation for topline results from the Phase 2 remlifanserin study in Alzheimer’s diseas…
Read attachment ↗